menu
    • menu
    [{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 AHS Virtual Annual Scientific Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Announces Publication of Positive Results of SNAP 101 Study for INP105","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel Neuropharma Presents Data from Pivotal Phase 3 Registration Study of INP104 for the Treatment of Acute Migraine at 2020 Migraine Trust Virtual Symposium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel Neuropharma Announces FDA Submission of New Drug Application For INP104 For The Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Oxford Finance LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Financing","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Oxford Finance LLC","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Oxford Finance LLC"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Announces Trudhesa\u2122 (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Provides Updates on Trudhesa\u2122 Launch and Recent Business Highlights","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$50.0 million","newsHeadline":"Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Oaktree Capital","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Oaktree Capital"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel Pharmaceuticals to Present Trudhesa Data at the 64th Annual Meeting of the American Headache Society","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Impel Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Impel Pharmaceuticals

    Menu

    Impel Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olanzapine

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitati...

                            Details : INP105 (olanzapine) is being developed as an acute treatment for agitation in persons with autism spectrum disorder (ASD) using Impel’s proprietary Precision Olfactory Delivery (POD®) technology which delivers drugs to the upper nasal space.

                            Brand Name : INP105

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 19, 2022

                            Lead Product(s) : Olanzapine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Impel Pharmaceuticals to Present Trudhesa Data at the 64th Annual Meeting of the American Headache Society

                            Details : Trudhesa (Dihydroergotamine Mesylate), is a single use, drug-device combination product containing a vial of DHE, gently delivers DHE—a proven, well-established therapeutic6—quickly to the bloodstream through the vascular-rich upper nasal space.

                            Brand Name : Trudhesa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 09, 2022

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Oaktree Capital

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree

                            Details : This non-dilutive financing provides Impel with immediate and sufficient capital to support the continued successful launch and commercialization efforts for Trudhesa.

                            Brand Name : Trudhesa

                            Molecule Type : Small molecule

                            Upfront Cash : $50.0 million

                            March 17, 2022

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Oaktree Capital

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights

                            Details : Using Impel’s proprietary POD® technology, Trudhesa delivers dihydroergotamine mesylate (DHE)—a proven, well-established therapeutic for acute migraine for adults—quickly to the bloodstream through the vascular-rich upper nasal space.

                            Brand Name : Trudhesa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 18, 2022

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescrip...

                            Details : In the trial, Trudhesa was generally well tolerated and exploratory efficacy findings showed it provided rapid, sustained, and consistent symptom relief.

                            Brand Name : Trudhesa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 28, 2021

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Oxford Finance LLC

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valle...

                            Details : This strategic debt financing increases companies balance sheet strength and firmly positions us to execute upon the potential launch and commercialization of TRUDHESA™ for the treatment of patients with acute migraine.

                            Brand Name : Trudhesa

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 07, 2021

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Oxford Finance LLC

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Impel Neuropharma Announces FDA Submission of New Drug Application For INP104 For The Acute Treatment of Migra...

                            Details : The NDA submission for INP104 is supported by safety results from the pivotal Phase 3 STOP 301 study, in which over 5,650 migraine attacks were treated over 24 or 52 weeks.

                            Brand Name : INP104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 09, 2020

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Impel Neuropharma Presents Data from Pivotal Phase 3 Registration Study of INP104 for the Treatment of Acute M...

                            Details : Within two hours of receiving their first dose of INP104, 38% of all patients reported freedom from migraine pain, 52% had freedom from their most bothersome migraine symptom (MBS) and 66.3% experienced pain relief.

                            Brand Name : INP104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 08, 2020

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olanzapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Impel NeuroPharma Announces Publication of Positive Results of SNAP 101 Study for INP105

                            Details : Study shows INP105 achieves rapid absorption which may provide an effective, convenient, & noninvasive future alternative for treating acute agitation in the home, community, or hospital setting.

                            Brand Name : INP105

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 30, 2020

                            Lead Product(s) : Olanzapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Impel Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 AHS Virtual Annual ...

                            Details : Impel Neuropharma presented additional findings from pivotal Phase 3 STOP 301 study, which further illustrates INP104’s potential to become an important new option for patients in the treatment of acute migraine.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 15, 2020

                            Lead Product(s) : Dihydroergotamine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth